|Address||Azinhaga Sta. Comba, Celas
|Platforms||Biomarkers, Imaging & Tracing|
AIBILI – Association for Innovation and Biomedical Research on Light and Image is a Research Technology Organisation dedicated to the development and clinical research of new products for medical therapy and diagnostic imaging. It is a private non-profit organisation, founded in 1989, established to support translational research and technology transfer in the health area.
As an Interface Centre in the health area, AIBILI acts in facilitating partner between scientific institutions, healthcare providers, enterprises and industry in order to bring novel products to the market.
AIBILI is ISO 9001 certified for all its activities and has a Data Centre certified by ECRIN-ERIC.
The main goals of AIBILI are clinical research in order to test novel therapies and innovative products by converting research knowledge into clinical practice.
AIBILI has a long-standing tradition of clinical research in ophthalmology, with a particular focus on Diabetic Retinopathy and Age-Related Macular degeneration, being internationally recognized for its innovations in the area of imaging biomarkers in ophthalmology.
Its coordination activities, nationally and across Europe, include Study Design, development of the Clinical Study, protocol submission to the Regulatory Authorities, coordination of the Participating Centres, Database development, Statistical Analysis, Pharmacovigilance, publication, as well as evaluation of the Economic Viability of the entire translation process.
AIBILI is the Coordinating Centre of EVICR.net – European Vision Institute Clinical Research Network, which is a platform for multinational clinical research in Ophthalmology bringing together 101 clinical research centres from 15 countries.
Imaging and Biomarkers
AIBILI has the capabilities to be involved in the biomarkers and imaging EATRIS platforms, which in part complement each other in this Research Organisation.
AIBILI has dedicated research lines focused on the development, testing, and validation of cognitive computing methods applied to state-of-art eye imaging data to be used in the screening and management of eye disease, with the final goal of identify novel tools and biomarkers in the diagnostics and prognostics of these conditions.
Indeed, AIBILI’s team contributed to the identification of biomarkers for disease progression, such as microaneurysm turnover in diabetic retinopathy, taking advantage of the Retmarker® software, and by accessing non-invasively changes in the Blood-Retinal Barrier using OCT-Leakage (developed at AIBILI and under patent application). Additional achievements have been made with multimodal imaging analysis to explore distinct phenotypes on the progression of Diabetic Retinopathy.
The implementation of novel hybrid algorithms that combine classical image processing methods with advanced machine learning methods such as deep learning, is one of the current main projects at AIBILI, and will contribute for validation of the potential biomarkers in the clinical setting.